REGiMMUNE Phase 2a Results of RGI-2001, an Activator of Invariant Natural Killer T Cells, Published in "Biology of Blood and Marrow Transplantation"
March 09, 2017 08:00 ET
|
REGiMMUNE
TOKYO, JAPAN--(Marketwired - Mar 9, 2017) - REGiMMUNE Corporation (RGI) is pleased to announce the publication of its Phase 2a clinical trial results for RGI-2001, a novel liposomal formulation of...
REGiMMUNE Announces Collaboration With JDRF and Pfizer Inc. for Type 1 Diabetes Prevention and Treatment Promoting Regulatory T-Cells
April 14, 2015 13:00 ET
|
REGiMMUNE
TOKYO, JAPAN--(Marketwired - Apr 14, 2015) - REGiMMUNE Corporation (RGI) and JDRF today announced a partnership, along with financial assistance and scientific expertise from Pfizer Inc., for a...
REGiMMUNE to Present Its Method for Long-Term Tolerance in Organ Transplantation at World Transplant Congress in San Francisco
July 25, 2014 08:00 ET
|
REGiMMUNE
TOKYO, JAPAN--(Marketwired - Jul 25, 2014) - REGiMMUNE Corporation, a biotechnology company focused on the development of immune regulatory therapeutics with its reVax technology, announced that it...
American Journal of Transplantation Reports REGiMMUNE's Preclinical Results of Its Method for Long-Term Tolerance in Organ Transplantation
February 28, 2014 03:01 ET
|
REGiMMUNE
TOKYO, JAPAN--(Marketwired - Feb 28, 2014) - REGiMMUNE Corporation announced that the American Journal of Transplantation (AJT) has published its paper that describes a novel approach to long-term...
REGiMMUNE Completes $9.2 Million Series D Financing
February 14, 2014 08:00 ET
|
REGiMMUNE
TOKYO, JAPAN--(Marketwired - Feb 14, 2014) - REGiMMUNE Corporation announced the closing of a Series D financing earlier this month. The company raised $9.2 million US in this new round, which was...
REGiMMUNE Begins Enrollment for Phase II Clinical Trial for Graft Versus Host Disease
February 06, 2014 10:15 ET
|
REGiMMUNE
TOKYO, JAPAN--(Marketwired - Feb 6, 2014) - REGiMMUNE Corporation announced today that it has begun a Phase II study of its proprietary compound RGI-2001 for GvHD associated with hematopoietic stem...
REGiMMUNE Initiates Phase I/II Clinical Trial for GvHD
January 31, 2012 19:21 ET
|
REGiMMUNE
TOKYO--(Marketwire - Jan 31, 2012) - REGiMMUNE Corporation said today that it has begun a Phase I/II study of its proprietary compound RGI-2001 for Graft versus Host Disease (GvHD) associated with...
REGiMMUNE Presents New ToleroVax Data at the 2010 American Transplant Congress
May 04, 2010 17:15 ET
|
REGiMMUNE
SAN DIEGO, CA--(Marketwire - May 4, 2010) - REGiMMUNE Corporation said today that data from a preclinical study showed enhanced immune suppression when ToleroVax (RGI-2001), its lead product...
REGiMMUNE to Present Data From Preclinical Study of RGI-2001 at the 2010 American Transplant Congress
April 28, 2010 08:00 ET
|
REGiMMUNE
MOUNTAIN VIEW, CA--(Marketwire - April 28, 2010) - REGiMMUNE Corporation will present new preclinical data of the company's lead product, RGI-2001 (ToleroVax), at the 2010 American Transplant...
Astellas and REGiMMUNE to Collaborate on New Vaccine Technology
July 22, 2009 03:00 ET
|
REGiMMUNE
TOKYO and MOUNTAIN VIEW, CA--(Marketwire - July 22, 2009) - REGiMMUNE Corporation today
announced that Astellas Pharma Inc. and REGiMMUNE have entered into a
collaboration agreement to jointly...